4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic a cid manufacturers
- CD2665
-
- $40.00
-
2026-05-11
- CAS:170355-78-9
- Purity: 99.71%
- Supply Ability: 10g
- CD2665
-
- $40.00
-
2026-04-20
- CAS:170355-78-9
- Purity: 99.71%
- Supply Ability: 10g
|
| | 4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic a cid Basic information |
| Product Name: | 4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic a cid | | Synonyms: | 4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic a cid;4-[6-[(2-Methoxyethoxy)methoxy]-7-tricyclo[3.3.1.13,7]dec-1-yl-2-naphthalenyl)benzoicacid;CD 2665;4-[7-(1-ADAMANTYL)-6-(2-METHOXYETHOXYMETHOXY)NAPHTHALEN-3-YL]BENZOIC ACID;Benzoic acid, 4-[6-[(2-methoxyethoxy)methoxy]-7-tricyclo[3.3.1.13,7]dec-1-yl-2-naphthalenyl]-;4-(7-((3r,5r,7r)-adamantan-1-yl)-6-((2-methoxyethoxy)methoxy)naphthalen-2-yl)benzoic acid;CD2665,CD-2665;CD2665, 10 mM in DMSO | | CAS: | 170355-78-9 | | MF: | C31H34O5 | | MW: | 486.6 | | EINECS: | | | Product Categories: | | | Mol File: | 170355-78-9.mol | ![4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic a cid Structure](CAS/GIF/170355-78-9.gif) |
| | 4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic a cid Chemical Properties |
| Boiling point | 668.6±55.0 °C(Predicted) | | density | 1.227±0.06 g/cm3(Predicted) | | storage temp. | Store at +4°C | | solubility | DMF: 30 mg/ml; DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml; DMSO: 25 mg/ml | | form | A crystalline solid | | pka | 4.13±0.10(Predicted) | | color | White to off-white |
| | 4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic a cid Usage And Synthesis |
| Uses | CD 2665 is a selective RARβ/γ antagonist. | | Biological Activity | Selective RAR β / γ antagonist (K D values are 110, 306 and > 1000 nM for RAR γ , RAR β and RAR α respectively). Blocks retinoic acid-induced apoptosis ex vivo . | | in vivo | CD2665 (0.6 mg/kg; Subcutaneous injection; daily, for 22 days) completely inhibits the overexpression of RARβ mRNA in the brain of alcohol treated mice[2]. CD2665 is a selective retinoid antagonist and elicits the expected maturation delay and growth plate expansion[3]. | Animal Model: | Mice submitted to 10 months of ethanol consumption[2]. | | Dosage: | 0.6 mg/kg | | Administration: | Subcutaneous injection; daily, for 22 days. | | Result: | Decreased brain RARβ mRNA levels (50% relative to control), without any change in RXR β/γ mRNA levels.
|
| Animal Model: | Male and female mice (3 weeks)[3]. | | Dosage: | 1.6 mg/kg | | Administration: | Oral gavage/intragastric; daily, for 31 days. | | Result: | Growth plate closure had largely been prevented in LDE225/antagonist co-treated mice compared with those receiving LDE225 only. |
| | storage | Store at +4°C |
| | 4-[7-(1-adamantyl)-6-(2-methoxyethoxymethoxy)naphthalen-2-yl]benzoic a cid Preparation Products And Raw materials |
|